273 related articles for article (PubMed ID: 37378095)
1. Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review.
Khan MA; Khan FH; Khan HB; Saadeh C; Davey N
Cureus; 2023 May; 15(5):e39553. PubMed ID: 37378095
[TBL] [Abstract][Full Text] [Related]
2. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
Bao A; Petri MA; Fava A; Kang J
Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38114267
[TBL] [Abstract][Full Text] [Related]
3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
4. Anifrolumab for treatment of refractory cutaneous lupus erythematosus.
Blum FR; Sampath AJ; Foulke GT
Clin Exp Dermatol; 2022 Nov; 47(11):1998-2001. PubMed ID: 35844070
[TBL] [Abstract][Full Text] [Related]
5. A case of Rowell syndrome with excellent improvement following anifrolumab.
Shope C; Andrews L; Cunningham M; Connett J
JAAD Case Rep; 2023 Jan; 31():27-30. PubMed ID: 36478979
[No Abstract] [Full Text] [Related]
6. Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature.
Paolino G; Ramirez GA; Calabrese C; Moroni L; Bianchi VG; Bozzolo EP; Mercuri SR; Dagna L
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001905
[TBL] [Abstract][Full Text] [Related]
7. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach.
Plüß M; Piantoni S; Wincup C; Korsten P
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743519
[TBL] [Abstract][Full Text] [Related]
8. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
Carter LM; Wigston Z; Laws P; Vital EM
Br J Dermatol; 2023 Jul; 189(2):210-218. PubMed ID: 36944572
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.
Foulke G; Helm LA; Clebak KT; Helm M
FP Essent; 2023 Mar; 526():25-36. PubMed ID: 36913660
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus.
Azuma N; Natsuaki M; Hashimoto N; Abe T; Ueda S; Ohno Y; Jinnin M; Matsui K
Mod Rheumatol Case Rep; 2024 Apr; ():. PubMed ID: 38597902
[TBL] [Abstract][Full Text] [Related]
11. Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report.
Mukkera S; Mannem M; Chamarti K; Pillarisetty L; Vulasala SS; Alahari L; Ammu A; Mukkera A; Vadlapatla RK
Cureus; 2022 Feb; 14(2):e22639. PubMed ID: 35242484
[TBL] [Abstract][Full Text] [Related]
12. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.
Lu Q; Long H; Chow S; Hidayat S; Danarti R; Listiawan Y; Deng D; Guo Q; Fang H; Tao J; Zhao M; Xiang L; Che N; Li F; Zhao H; Lau CS; Ip FC; Ho KM; Paliza AC; Vicheth C; Godse K; Cho S; Seow CS; Miyachi Y; Khang TH; Ungpakorn R; Galadari H; Shah R; Yang K; Zhou Y; Selmi C; Sawalha AH; Zhang X; Chen Y; Lin CS
J Autoimmun; 2021 Sep; 123():102707. PubMed ID: 34364171
[TBL] [Abstract][Full Text] [Related]
13. Treatment With Voclosporin and Anifrolumab in a Patient With Lupus Nephritis and Refractory Discoid Lupus Erythematosus: A Case Report and Literature Review.
Karagenova R; Vodusek Z; Krimins R; Krieger A; Timlin H
Cureus; 2024 Mar; 16(3):e55321. PubMed ID: 38559540
[TBL] [Abstract][Full Text] [Related]
14. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S; Ehreiser L; Anders J; Anders HJ
Front Immunol; 2022; 13():999704. PubMed ID: 36211360
[TBL] [Abstract][Full Text] [Related]
15. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
16. An update on clinical trials for cutaneous lupus erythematosus.
Xie L; Lopes Almeida Gomes L; Stone CJ; Faden DF; Werth VP
J Dermatol; 2024 Mar; ():. PubMed ID: 38491743
[TBL] [Abstract][Full Text] [Related]
17. An update on the management of refractory cutaneous lupus erythematosus.
Verdelli A; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Volpi W; Quintarelli L; Caproni M
Front Med (Lausanne); 2022; 9():941003. PubMed ID: 36213629
[TBL] [Abstract][Full Text] [Related]
18. Rowell Syndrome in Nigeria: Systemic Lupus Erythematosus Presenting as Recurrent Erythema Multiforme in a Young Woman.
Akintayo RO; Olarinoye GM; Akintayo FC; Ilesanmi ON
Acta Dermatovenerol Croat; 2019 Sep; 27(3):200-201. PubMed ID: 31542069
[TBL] [Abstract][Full Text] [Related]
19. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
